Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Omega Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$908,814

70 payments

Through program year 2025, Omega Clinical Trials is reported as receiving $908,814 in research payments, across 70 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $49,837 6
2024 Research $502,139 14
2023 Research $233,450 7
2022 Research $27,569 8
2021 Research $12,026 4
2020 Research $7,000 1
2019 Research $76,794 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $421,620 6 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $210,759 13 payments
  3. AbbVie, Inc. $150,712 10 payments
  4. Allergan Inc. $66,553 11 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $21,038 3 payments
  6. Neurocrine Biosciences, Inc. $15,061 22 payments
  7. Biogen, Inc. $14,206 2 payments
  8. Boehringer Ingelheim RCV GmbH & Co KG $8,865 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $325,881 2 payments
  2. A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features $149,750 8 payments
  3. BI 425809 Pivotal efficacy study 1 $104,313 5 payments
  4. Connex 1 $66,188 3 payments
  5. Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) $46,243 1 payment
  6. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $41,250 2 payments
  7. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $35,982 4 payments
  8. Connex-X $33,101 3 payments
  9. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $19,251 4 payments
  10. An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) $16,022 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record